Sartaj Tabassum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4934103/publications.pdf

Version: 2024-02-01

		109137	161609
138	3,761	35	54
papers	citations	h-index	g-index
139	139	139	3950
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Biophysical binding profile with ct-DNA and cytotoxic studies of a modulated nanoconjugate of umbelliferone cobalt oxide loaded on graphene oxide (GO) as drug carrier. Journal of Biomolecular Structure and Dynamics, 2022, 40, 4558-4569.	2.0	7
2	Deciphering the effect of hydrophobicity on protein binding interaction in cobalt(II) complexes by multispectroscopic and computational methods. Journal of Biomolecular Structure and Dynamics, 2022, 40, 7381-7393.	2.0	3
3	Metal complexes of NSAIDs as potent anti-tumor chemotherapeutics: Mechanistic insights into cytotoxic activity via multiple pathways primarily by inhibition of $COXâE^{"}1$ and $COXâE^{"}2$ enzymes. Coordination Chemistry Reviews, 2022, 453, 214316.	9.5	11
4	Synthesis, structural characterization, in vitro comparative DNA/RNA binding, and computational studies of half-sandwich Ru (II)(Æž6-p-cymene) aminoquinoline complex. Polyhedron, 2022, 213, 115618.	1.0	3
5	Comprehensive biological {DNA/RNA binding profile, cleavage &cytotoxicity activity} of structurally well-characterized chromone-appended Cu(II)(L1-3)(phen) potential anticancer drug candidates. Polyhedron, 2022, 214, 115638.	1.0	10
6	A chromone-based colorimetric fluorescence sensor for selective detection of Cu2+ions, and its application for in-situ imaging. Journal of Molecular Structure, 2022, 1256, 132533.	1.8	15
7	Chromoneâ€Appended Zn(II) tRNAâ€Targeted Potential Anticancer Chemotherapeutic Agent: Structural Details, <i>inâ€vitro</i> ctâ€DNA/tRNA Binding, Cytotoxicity Studies And Antioxidant Activity. ChemistrySelect, 2022, 7, .	0.7	5
8	ROS -mediated anticancer response of potent copper(II) drug entities derived from S, O and N, N chelating donor scaffold: Single X-ray crystal diffraction and spectroscopic studies. Journal of Molecular Structure, 2022, , 132989.	1.8	O
9	Functionalized graphene oxide loaded GATPT as rationally designed vehicle for cancer-targeted drug delivery. Journal of Drug Delivery Science and Technology, 2022, 71, 103281.	1.4	2
10	Synthesis, Structure Elucidation by Multi-spectroscopic Techniques and Single-crystal X-ray Diffraction of Promising Fluoro/Bromo-substituted-chromone(bpy)copper(II) Anticancer Drug Entities. Inorganica Chimica Acta, 2022, , 120967.	1.2	4
11	Comprehensive structural {single crystal X-raydiffraction, spectroscopic & DFT computational simulation} and biological {in vitro DNA binding & DRA samp; antibacterial} studies of polymeric copper(â;)-based imidazole drug entity. Inorganica Chimica Acta, 2022, 538, 120978.	1.2	1
12	"Turn–on―benzophenone based fluorescence and colorimetric sensor for the selective detection of Fe2+ in aqueous media: Validation of sensing mechanism by spectroscopic and computational studies. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 247, 119156.	2.0	29
13	Organometallic ruthenium (Î- ⁶ - <i>p</i> -cymene) complexes interfering with quorum sensing and biofilm formation: an anti-infective approach to combat multidrug-resistance in bacteria. New Journal of Chemistry, 2021, 45, 2184-2199.	1.4	5
14	Biochemical pathways of copper complexes: progress over the past 5 years. Drug Discovery Today, 2021, 26, 1086-1096.	3.2	47
15	Structural characterization, theoretical investigation and sensing activity of a novel Cu(II)–based 1D metal coordination polymer. Inorganic Chemistry Communication, 2021, 126, 108473.	1.8	6
16	Multi-Component One-Pot Assisted Synthesis, Anti-bacterial Capabilities, and Scanning Electron Microscopy of Novel Corticosteroid Thiopyran. Current Organic Synthesis, 2021, 18, 411-417.	0.7	2
17	Elucidating the interaction of enantiomeric Cu(II) complexes with DNA, RNA and HSA: A comparative study. Polyhedron, 2021, 210, 115501.	1.0	5
18	Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives. Coordination Chemistry Reviews, 2021, 445, 214104.	9.5	59

#	Article	IF	Citations
19	Design, synthesis, ligand's scaffold variation and structure elucidation of Cu(II) complexes; In vitro DNA binding, morphological studies and their anticancer activity. Polyhedron, 2021, 209, 115450.	1.0	6
20	A novel biocompatible formate bridged 1D-Cu(<scp>ii</scp>) coordination polymer induces apoptosis selectively in human lung adenocarcinoma (A549) cells. Dalton Transactions, 2021, 50, 2253-2267.	1.6	5
21	Structure elucidation, <i>in vitro</i> binding studies and ROS-dependent anti-cancer activity of Cu(II) and Zn(II) phthaloylglycinate(phen) complexes against MDA-MB-231 cells. Metallomics, 2021, 13, .	1.0	8
22	Interaction of Carrier Protein with Potential Metallic Drug Candidate N-Glycoside â€~GATPT': Validation by Multi-Spectroscopic and Molecular Docking Approaches. Molecules, 2021, 26, 6641.	1.7	1
23	Synthesis and characterization of heterobimetallic SnIV–CuII/ZnII complexes: DFT studies, cleavage potential and cytotoxic activity. Journal of Biomolecular Structure and Dynamics, 2020, 38, 1130-1142.	2.0	10
24	Evaluation of cytotoxic potential of structurally well-characterized RNA targeted ionic non-steroidal anti-inflammatory (NSAID) Cu(⟨scp⟩ii⟨/scp⟩) & Zn(⟨scp⟩ii⟨/scp⟩) DACH–mefenamato drug conjugates against human cancer cell lines. RSC Advances, 2020, 10, 166-178.	1.7	29
25	Structure elucidation {spectroscopic, single crystal X-ray diffraction and computational DFT studies} of new tailored benzenesulfonamide derived Schiff base copper(II) intercalating complexes: Comprehensive biological profile {DNA binding, pBR322 DNA cleavage, Topo I inhibition and cytotoxic activity}. Bioorganic Chemistry, 2020, 94, 103427.	2.0	32
26	Water soluble ionic Co(<scp>ii</scp>), Cu(<scp>ii</scp>) and Zn(<scp>ii</scp>) diimine–glycinate complexes targeted to tRNA: structural description, <i>in vitro</i> comparative binding, cleavage and cytotoxic studies towards chemoresistant prostate cancer cells. Dalton Transactions, 2020, 49, 16830-16848.	1.6	24
27	Structure of Imidazolium-N-phthalolylglycinate Salt Hydrate: Combined Experimental and Quantum Chemical Calculations Studies. Crystals, 2020, 10, 91.	1.0	1
28	Structural, Spectroscopic, and Chemical Bonding Analysis of Zn(II) Complex [Zn(sal)](H2O): Combined Experimental and Theoretical (NBO, QTAIM, and ELF) Investigation. Crystals, 2020, 10, 259.	1.0	13
29	Synthesis of homo- and hetero-metallic cobalt and zinc nano oxide particles by a calcination process using coordination compounds: their characterization, DFT calculations and capacitance behavioural study. RSC Advances, 2020, 10, 13126-13138.	1.7	4
30	Multispectroscopic insight, morphological analysis and molecular docking studies of Cull-based chemotherapeutic drug entity with human serum albumin (HSA) and bovine serum albumin (BSA). Journal of Biomolecular Structure and Dynamics, 2019, 37, 3290-3304.	2.0	39
31	Clinical developments of antitumor polymer therapeutics. RSC Advances, 2019, 9, 24699-24721.	1.7	47
32	Coumarin Derived "Turn on―Fluorescent Sensor for Selective Detection of Cadmium (II) Ion: Spectroscopic Studies and Validation of Sensing Mechanism by DFT Calculations. Journal of Fluorescence, 2019, 29, 1029-1037.	1.3	26
33	Fluorescent delivery vehicle containing cobalt oxide–umbelliferone nanoconjugate: DNA/protein interaction studies and anticancer activity on MF7 cancer cell line. RSC Advances, 2019, 9, 26503-26518.	1.7	7
34	Synthesis, structural investigations and DNA cleavage properties of a new water soluble Cu(II)–iminodiacetate complex. Inorganic Chemistry Communication, 2019, 106, 48-53.	1.8	9
35	Catalytic induced morpholical transformation of porous ZnO to ZnO nanorods by Sn(IV) and their effect on photocatalytic reduction of methylene blue and DFT calculations. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019, 220, 117101.	2.0	2
36	Spectroscopic and singleâ€crystal Xâ€ray diffraction studies of enantiomeric copper(II) Schiff base oneâ€dimensional coordination polymers with 4â€(2â€aminoethyl)benzenesulfonamide appendage: Comprehensive biological evaluation (DNA binding, cleavage, superoxide dismutase mimetic activity,) Tj ETQq0	0 0 rgBT /0	Overlock 10 Tf

#	Article	IF	CITATIONS
37	Evaluation of cytotoxic activity and genotoxicity of structurally well characterized potent cobalt(II) phen–based antitumor drug entities: An in vitro and in vivo approach. Bioorganic Chemistry, 2019, 88, 102963.	2.0	12
38	Development and future prospects of selective organometallic compounds as anticancer drug candidates exhibiting novel modes of action. European Journal of Medicinal Chemistry, 2019, 175, 269-286.	2.6	52
39	Design and synthesis of a DNA intercalative half-sandwich organoruthenium(<scp>ii</scp>)–chromone complex: cytotoxicity evaluation and topoisomerase lα inhibition assay. New Journal of Chemistry, 2019, 43, 5475-5487.	1.4	22
40	Recent advances in metallodrug-like molecules targeting non-coding RNAs in cancer chemotherapy. Coordination Chemistry Reviews, 2019, 387, 47-59.	9.5	30
41	Modulation of amyloid fibril formation of plasma protein by saffron constituent "safranal― Spectroscopic and imaging analyses. International Journal of Biological Macromolecules, 2019, 127, 529-535.	3.6	12
42	Cadmiumâ€induced neurodegeneration and activation of noncanonical sonic hedgehog pathway in rat cerebellum. Journal of Biochemical and Molecular Toxicology, 2019, 33, e22274.	1.4	6
43	Evaluation of (\acute{E}^3 ⁶ - <i>p-</i> cymene) ruthenium diclofenac complex as anticancer chemotherapeutic agent: interaction with biomolecules, cytotoxicity assays. Journal of Biomolecular Structure and Dynamics, 2019, 37, 3905-3913.	2.0	10
44	Carbohydrate-based heteronuclear complexes as topoisomerase lÎ \pm inhibitor: approach toward anticancer chemotherapeutics. Journal of Biomolecular Structure and Dynamics, 2019, 37, 1494-1510.	2.0	15
45	Tetranuclear cubane Cu4O4 complexes as prospective anticancer agents: Design, synthesis, structural elucidation, magnetism, computational and cytotoxicity studies. Inorganica Chimica Acta, 2018, 473, 121-132.	1.2	16
46	Single X-ray crystal structure, DFT studies and topoisomerase I inhibition activity of a tailored ionic Ag(<scp>i</scp>) nalidixic acid–piperazinium drug entity specific for pancreatic cancer cells. New Journal of Chemistry, 2018, 42, 506-519.	1.4	20
47	New Ionic Cu(II) and Co(II) DACH–Flufenamate Conjugate Complexes: Spectroscopic Characterization, Single X–Ray Studies and Cytotoxic Activity on Human Cancer Cell Lines. ChemistrySelect, 2018, 3, 12764-12772.	0.7	11
48	A zwitterionic Zn(II) benzothiazole nanohybrid conjugate as hydrolytic DNA cleavage agent. Inorganic Chemistry Communication, 2018, 93, 69-72.	1.8	9
49	<i>\hat{l}^2</i> -Carboline Silver Compound Binding Studies with Human Serum Albumin: A Comprehensive Multispectroscopic Analysis and Molecular Modeling Study. Bioinorganic Chemistry and Applications, 2018, 1-11.	1.8	10
50	Cu II -Na I heteronuclear complex as anticancer entity against human breast cancer cell lines: DNA binding, cleavage, and Computational studies. Inorganica Chimica Acta, 2018, 479, 229-239.	1.2	14
51	Synthesis of chiral R/S-pseudopeptide-based Cu(<scp>ii</scp>) & amp; Zn(<scp>ii</scp>) complexes for use in targeted delivery for antitumor therapy: enantiomeric discrimination with CT-DNA and pBR322 DNA hydrolytic cleavage mechanism. RSC Advances, 2017, 7, 6587-6597.	1.7	25
52	Synthesis and structure elucidation of new open cubane tetranuclear [Cu II 4] Cluster: Evaluation of the DNA/HSA interaction and pBR322 DNA cleavage pathway and cytotoxicity. Inorganica Chimica Acta, 2017, 463, 142-155.	1.2	10
53	Loss of DUSP3 activity radiosensitizes human tumor cell lines via attenuation of DNA repair pathways. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1879-1894.	1.1	11
54	Heteroleptic Copper(I) Complexes of "Scorpionate―Bis-pyrazolyl Carboxylate Ligand with Auxiliary Phosphine as Potential Anticancer Agents: An Insight into Cytotoxic Mode. Scientific Reports, 2017, 7, 45229.	1.6	42

#	Article	IF	CITATIONS
55	Chiral transition metal complexes: Synthetic approach and biological applications. Inorganica Chimica Acta, 2017, 458, 8-27.	1.2	23
56	Biological evaluation of dinuclear copper complex/dichloroacetic acid cocrystal against human breast cancer: design, synthesis, characterization, DFT studies and cytotoxicity assays. RSC Advances, 2017, 7, 47920-47932.	1.7	38
57	Coumarin centered copper(<scp>ii</scp>) complex with appended-imidazole as cancer chemotherapeutic agents against lung cancer: molecular insight via DFT-based vibrational analysis. RSC Advances, 2017, 7, 36056-36071.	1.7	45
58	Human Topoisomerase I mediated cytotoxicity profile of l-valine-quercetin diorganotin(IV) antitumor drug entities. Journal of Organometallic Chemistry, 2016, 823, 23-33.	0.8	19
59	Synthesis and crystal structure determination of cobalt(II) mixed-ligand complex containing 1,10-phenanthroline and 5-(2-carboxybenzyloxy)isophthalic acid: Their biological evaluation viz. DNA/protein binding profile, pBR322 DNA cleavage activity. Inorganica Chimica Acta, 2016, 451, 216-226.	1.2	4
60	A comparative analyses of bioactive Cu(II) complexes using Hirshfeld surface and density functional theory (DFT) methods: DNA binding studies, cleavage and antibiofilm activities. Inorganica Chimica Acta, 2016, 453, 193-201.	1.2	20
61	Synthesis and crystal structure elucidation of new copper(II)-based chemotherapeutic agent coupled with 1,2-DACH and orthovanillin: Validated by in vitro DNA/HSA binding profile and pBR322 cleavage pathway. Journal of Photochemistry and Photobiology B: Biology, 2016, 161, 318-327.	1.7	15
62	Current and future potential of metallo drugs: Revisiting DNA-binding of metal containing molecules and their diverse mechanism of action. Inorganica Chimica Acta, 2016, 444, 1-22.	1.2	79
63	A dinuclear copper(II) complex with piperazine bridge ligand as a potential anticancer agent: DFT computation and biological evaluation. Inorganica Chimica Acta, 2016, 445, 167-178.	1.2	18
64	Synthesis and spectroscopic characterization of diorganotin(<scp>iv</scp>) complexes of N′-(4-hydroxypent-3-en-2-ylidene)isonicotinohydrazide: chemotherapeutic potential validation by in vitro interaction studies with DNA/HSA, DFT, molecular docking and cytotoxic activity. RSC Advances, 2015, 5, 50673-50690.	1.7	66
65	Synthesis and crystal structure determination of a mononuclear cobalt(<scp>ii</scp>) complex derived from 4-(pyridin-4-ylmethoxy)-benzoic acid: evaluation of the DNA/protein interaction and photo-induced pBR322 DNA cleavage. RSC Advances, 2015, 5, 35843-35851.	1.7	13
66	Mechanistic insights into a novel chromone-appended Cu(<scp>ii</scp>) anticancer drug entity: in vitro binding profile with DNA/RNA substrates and cytotoxic activity against MCF-7 and HepG2 cancer cells. Dalton Transactions, 2015, 44, 10330-10342.	1.6	87
67	A multifunctional molecular entity Cu ^{II} –Sn ^{IV} heterobimetallic complex as a potential cancer chemotherapeutic agent: DNA binding/cleavage, SOD mimetic, topoisomerase lα inhibitory and in vitro cytotoxic activities. RSC Advances, 2015, 5, 47439-47450.	1.7	31
68	Synthesis and characterization of Co(<scp>ii</scp>) and Fe(<scp>ii</scp>) peptide conjugates as hydrolytic cleaving agents and their preferential enantiomeric disposition for CT-DNA: structural investigation of <scp>I</scp> -enantiomers by DFT and molecular docking studies. RSC Advances, 2015, 5, 72121-72131.	1.7	20
69	Nuclear blebbing of biologically active organoselenium compound towards human cervical cancer cell (HeLa): InÂvitro DNA/HSA binding, cleavage and cell imaging studies. European Journal of Medicinal Chemistry, 2015, 90, 876-888.	2.6	61
70	Synthesis and structure elucidation of a cobalt(II) complex as topoisomerase I inhibitor: InÂvitro DNA binding, nuclease and RBC hemolysis. European Journal of Medicinal Chemistry, 2014, 74, 683-693.	2.6	36
71	New modulated design, docking and synthesis of carbohydrate-conjugate heterobimetallic Cull–SnIV complex as potential topoisomerase II inhibitor: InÂvitro DNA binding, cleavage and cytotoxicity against human cancer cell lines. European Journal of Medicinal Chemistry, 2014, 74, 694-702.	2.6	17
72	Synthesis and characterization of Cu(II)-based anticancer chemotherapeutic agent targeting topoisomerase Iα: InÂvitro DNA binding, pBR322 cleavage, molecular docking studies and cytotoxicity against human cancer cell lines. European Journal of Medicinal Chemistry, 2014, 74, 509-523.	2.6	51

#	Article	IF	CITATIONS
73	Heterobimetallic o-vanillin functionalized complexes: InÂvitro DNA binding validation, cleavage activity and molecular docking studies ofÂCull–Sn2IV analogs. Journal of Organometallic Chemistry, 2014, 752, 17-24.	0.8	13
74	Carbohydrate linked organotin(<scp>iv</scp>) complexes as human topoisomerase ll± inhibitor and their antiproliferative effects against the human carcinoma cell line. Dalton Transactions, 2014, 43, 2534-2548.	1.6	45
75	Synthesis and structure elucidation of a copper(II) Schiff-base complex: In vitro DNA binding, pBR322 plasmid cleavage and HSA binding studies. Journal of Photochemistry and Photobiology B: Biology, 2014, 140, 321-331.	1.7	66
76	Investigation of diorganotin(IV) complexes: Synthesis, characterization, in vitro DNA binding studies and cytotoxicity assessment of di-n-butyltin(IV) complex. Inorganica Chimica Acta, 2014, 423, 204-214.	1,2	18
77	Organo-tin antitumor compounds: Their present status in drug development and future perspectives. Inorganica Chimica Acta, 2014, 423, 26-37.	1.2	95
78	Synthesis, structure elucidation and DFT studies of a new coumarin-derived Zn(<scp>ii</scp>) complex: in vitro DNA/HSA binding profile and pBR322 cleavage pathway. RSC Advances, 2014, 4, 43504-43515.	1.7	11
79	Synthesis and crystal structure determination of copper(II)-complex: InÂvitro DNA and HSA binding, pBR322 plasmid cleavage, cell imaging and cytotoxic studies. European Journal of Medicinal Chemistry, 2014, 83, 141-154.	2.6	56
80	Exploration of glycosylated-organotin(IV) complexes as anticancer drug candidates. Inorganica Chimica Acta, 2014, 423, 38-45.	1,2	15
81	DNA binding, docking studies, artificial nuclease activity and in vitro cytotoxicity of newly synthesized steroidal 1H–pyrimidines. Comptes Rendus Chimie, 2014, 17, 359-369.	0.2	8
82	Organometallic ruthenium(II) scorpionate as topo $ll\hat{l}_{\pm}$ inhibitor; inÂvitro binding studies with DNA, HPLC analysis and its anticancer activity. Journal of Organometallic Chemistry, 2014, 771, 47-58.	0.8	39
83	New modulated design and synthesis of quercetin–Cull/Znll–Sn2IV scaffold as anticancer agents: in vitro DNA binding profile, DNA cleavage pathway and Topo-I activity. Dalton Transactions, 2013, 42, 10029.	1.6	84
84	Design and synthesis of (S)- and (R)-enantiomers of [4-(2-hydroxy-1-phenylethylimino)pent-2-ol]dimethyltin(<scp>iv</scp>) and 2,2-dimethyl-4-phenyl-1,3,2-oxazastannolidine: in vitro antitumor activity against human tumor cell lines and in vivo assay of (S)-enantiomers. Dalton Transactions, 2013, 42, 3390-3401.	1.6	35
85	Chiral heterobimetallic complexes targeting human DNA-topoisomerase lα. Dalton Transactions, 2013, 42, 16749.	1.6	58
86	Synthesis and mechanistic insight of glycosylated Cull/Nillâ€"Sn2IV heterobimetallic DNA binding agents: Validation of a specific Cullâ€"Sn2IV chemotherapeutic agent for human leukemic cell line K-562. Journal of Organometallic Chemistry, 2013, 745-746, 226-234.	0.8	10
87	Mixed-ligand Cu(II)–vanillin Schiff base complexes; effect of coligands on their DNA binding, DNA cleavage, SOD mimetic and anticancer activity. European Journal of Medicinal Chemistry, 2013, 60, 216-232.	2.6	120
88	A Chloro-Bridged Heterobimetallic (η ⁶ -Arene)ruthenium–Organotin Complex as an Efficient Topoisomerase Iα Inhibitor. Organometallics, 2013, 32, 2546-2551.	1.1	41
89	Synthesis and characterization of copper(II) and zinc(II)-based potential chemotherapeutic compounds: Their biological evaluation viz. DNA binding profile, cleavage and antimicrobial activity. European Journal of Medicinal Chemistry, 2012, 58, 308-316.	2.6	110
90	DNA binding and cleavage studies of new sulfasalazine-derived dipeptide Zn(II) complex: Validation for specific recognition with $5\hat{a} \in \hat{a} \in \hat{a}$ (TMP. Journal of Luminescence, 2012, 132, 3058-3065.	1.5	20

#	Article	IF	CITATIONS
91	Synthesis of heterobimetallic complexes: In vitro DNA binding, cleavage and antimicrobial studies. Journal of Photochemistry and Photobiology B: Biology, 2012, 114, 108-118.	1.7	56
92	Synthesis, characterization and interaction studies of copper based drug with Human Serum Albumin (HSA): Spectroscopic and molecular docking investigations. Journal of Photochemistry and Photobiology B: Biology, 2012, 114, 132-139.	1.7	167
93	New heterobimetallic complex as potential topoisomerase I inhibitor: In vitro DNA binding, cleavage and cytotoxicity against human cancer cell lines. Journal of Photochemistry and Photobiology B: Biology, 2012, 115, 63-72.	1.7	43
94	Interaction and photo-induced cleavage studies of a copper based chemotherapeutic drug with human serum albumin: spectroscopic and molecular docking study. Molecular BioSystems, 2012, 8, 2424.	2.9	113
95	Design, synthesis, characterization and DNA-binding studies of a triphenyltin(iv) complex of N-glycoside (GATPT), a sugar based apoptosis inducer: in vitro and in vivo assessment of induction of apoptosis by GATPT. Metallomics, 2012, 4, 205-217.	1.0	28
96	Chiral nano heterobimetallic DNA receptors: InÂvitro binding studies, cleavage activity and DNA condensation studies (TEM and AFM imaging). Journal of Organometallic Chemistry, 2012, 713, 123-133.	0.8	9
97	Enantiomeric Specificity of Biologically Significant Cu(II) and Zn(II) Chromone Complexes Towards DNA. Chirality, 2012, 24, 977-986.	1.3	23
98	Molecular drug design, synthesis and structure elucidation of a new specific target peptide based metallo drug for cancer chemotherapy as topoisomerase I inhibitor. Dalton Transactions, 2012, 41, 4955.	1.6	73
99	New modulated design and synthesis of chiral Cull/SnIV bimetallic potential anticancer drug entity: In vitro DNA binding and pBR322 DNA cleavage activity. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2012, 90, 208-217.	2.0	11
100	Synthesis of Aryl-1,2,4,5-tetrazinane-3-thiones, in vitro DNA binding studies, nuclease activity and its antimicrobial activity. Journal of Molecular Structure, 2012, 1020, 33-40.	1.8	12
101	De novo design of chiral organotin cancer drug candidates: Validation of enantiopreferential binding to molecular target DNA and 5′-GMP by UV–visible, fluorescence, 1H and 31P NMR. Journal of Photochemistry and Photobiology B: Biology, 2011, 105, 167-174.	1.7	21
102	Carbohydrate-conjugate heterobimetallic complexes: synthesis, DNA binding studies, artificial nuclease activity and in vitro cytotoxicity. Carbohydrate Research, 2011, 346, 2886-2895.	1.1	21
103	Synthesis and enantiopreferential DNAâ€binding profile of late 3d transition metal <i>R</i> à€and <i>S</i> â€enantiomeric complexes derived from <i>N</i> , <i>N</i> â€bisâ€(1â€benzylâ€2â€ethoxyethane): Valida of <i>R</i> â€enantiomer of copper(II) complex as a human topoisomerase II inhibitor. Chirality, 2011, 23, 557-567.	tion 1.3	18
104	Synthesis and characterization of glycoconjugate tin(IV) complexes: In vitro DNA binding studies, cytotoxicity, and cell death. Journal of Organometallic Chemistry, 2011, 696, 1600-1608.	0.8	26
105	Interaction of a ruthenium(II)–chalcone complex with double stranded DNA: Spectroscopic, molecular docking and nuclease properties. Journal of Photochemistry and Photobiology A: Chemistry, 2011, 220, 145-152.	2.0	63
106	Cyclic Voltammetry-An Electrochemical Approach to Study Metal-based Potential Antitumor Drug-DNA Interaction. Current Analytical Chemistry, 2011, 7, 71-79.	0.6	17
107	Synthesis and Characterization of Glucose-Bis(pyrazole)-Cu(II)/Ni(II) Complexes and Their in Vitro DNA Binding Studies. Chemical and Pharmaceutical Bulletin, 2010, 58, 318-325.	0.6	3
108	Synthesis of carbohydrate-conjugate heterobimetallic Cull–Sn2IV and ZnIl–Sn2IV complexes; their interactions with CT DNA and nucleotides; DNA cleavage, in-vitro cytotoxicity. European Journal of Medicinal Chemistry, 2010, 45, 4797-4806.	2.6	31

#	Article	IF	CITATIONS
109	Synthesis, structural and spectroscopic characterization and biomimetic properties of new copper, manganese, zinc complexes: Identification of possible superoxide-dismutase mimics bearing hydroxyl radical generating/scavenging abilities. Journal of Inorganic Biochemistry, 2010, 104, 820-830.	1.5	41
110	DNA interaction studies of new nano metal based anticancer agent: validation by spectroscopic methods. Nanotechnology, 2010, 21, 195102.	1.3	29
111	Synthesis of new piperazine derived Cu(II)/Zn(II) metal complexes, their DNA binding studies, electrochemistry and anti-microbial activity: Validation for specific recognition of Zn(II) complex to DNA helix by interaction with thymine base. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2009, 72, 1026-1033.	2.0	61
112	Synthesis of new heterometallic macromolecules: Their DNA binding, cleavage activity and in vitro model electrochemotherapy study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2009, 74, 1152-1159.	2.0	6
113	Template synthesis of novel carboxamide dinuclear copper (II) complex: spectral characterization and reactivity towards calf-thymus DNA. BioMetals, 2008, 21, 299-310.	1.8	44
114	Identification of a Potent Inhibitor of Human Dualâ€Specific Phosphatase, VHR, from Computerâ€Aided and NMRâ€Based Screening to Cellular Effects. ChemBioChem, 2007, 8, 2092-2099.	1.3	30
115	Chemical and biotechnological developments in organotin cancer chemotherapy. Journal of Organometallic Chemistry, 2006, 691, 1761-1766.	0.8	188
116	New homodi-and heterotrinuclear metal complexes of Schiff base compartmental ligand: interaction studies of copper complexes with calf thymus DNA. Open Chemistry, 2006, 4, 502-522.	1.0	17
117	Synthesis of O,O Ethane Bridged Bis-copper(II) Macrocycles. Selective Enzyme Model for Catecholase Activity. Transition Metal Chemistry, 2006, 31, 237-245.	0.7	1
118	Cu(II) complexes as receptor molecules for development of new chloride sensors. Electrochimica Acta, 2006, 52, 408-414.	2.6	16
119	Synthesis and Characterization of a New Macrocyclic Copper(II) Complex with anN-Glycosidic Pendant Arm:in vitro Cytotoxicity and Binding Studies with Calf-Thymus DNA. Chemistry and Biodiversity, 2006, 3, 312-325.	1.0	19
120	New modulated metallic macrocycles: Electrochemistry and their interaction with calf thymus DNA. Acta Biomaterialia, 2005, 1, 677-689.	4.1	57
121	Synthesis of new dinuclear dicopper(II) and dinickel(II) complexes. The kinetics of catechol oxidase and electrochemistry of a dicopper(II) complex. Transition Metal Chemistry, 2005, 30, 128-135.	0.7	3
122	Synthesis and characterization of new synthetic oxygen carriers. A kinetic study of the reaction of the binuclear iron(III)?copper(II) complex with H2O2. Transition Metal Chemistry, 2005, 30, 196-204.	0.7	7
123	Novel Bimetallic Complexes of Copper, Nickel and Manganese Derived from the Cobalt(III) Complex and their Interaction Studies with Calf Thymus DNA. Transition Metal Chemistry, 2005, 30, 998-1007.	0.7	3
124	Synthesis, Characterization, Solution Stability Studies, Electrochemistry, and DNAâ€Binding Behavior of Cu(II) Complexes of <scp>D < /scp>â€Gluconic Acid. Journal of Carbohydrate Chemistry, 2005, 24, 865-887.</scp>	0.4	9
125	p53-Dependent Apoptotic Mechanism of a New Designer Bimetallic Compound Tri-phenyl Tin Benzimidazolethiol Copper Chloride (TPT-CuCl2): In Vivo Studies in Wistar Rats as Well as in Vitro Studies in Human Cervical Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2004. 311. 22-33.	1.3	40
126	Triphenyl Tin Benzimidazolethiol, a Novel Antitumor Agent, Induces Mitochondrial-Mediated Apoptosis in Human Cervical Cancer Cells via Suppression of HPV-18 Encoded E6. Journal of Biochemistry, 2003, 134, 521-528.	0.9	45

#	Article	IF	CITATIONS
127	Synthesis and Characterization of the Copper(II) Complex with 2,2â€bis(1H,3H,5H)Pyrimidineâ€4,6â€dioneâ€1,2â€diiminoethane: Fluorescence Quenching Studies in Proteins. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2003, 33, 509-517.	1.8	1
128	Interaction of a new cobalt(II) complex of five-coordinated chiral porphyrin with calf thymus DNA. Transition Metal Chemistry, 2002, 27, 256-261.	0.7	7
129	New metal compounds and their reactivity towards bovine milk casein. Transition Metal Chemistry, 2002, 27, 776-781.	0.7	2
130	Title is missing!. Transition Metal Chemistry, 2002, 27, 741-747.	0.7	12
131	SYNTHESIS, CHARACTERIZATION, AND TOXICITY OF HETEROBINUCLEAR COMPLEXES OF TRANSITION METAL IONS. Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2001, 31, 1803-1815.	1.8	11
132	Title is missing!. Transition Metal Chemistry, 2001, 26, 426-429.	0.7	33
133	Title is missing!. Transition Metal Chemistry, 2001, 26, 574-580.	0.7	8
134	Synthesis of new 14- and 16-membered macrocycles and their transition metal complexes. Transition Metal Chemistry, 1996, 21, 97-100.	0.7	1
135	Chelating behaviour of new 12-membered Schiff base macrocycles containing pendant groups. Transition Metal Chemistry, 1995, 20, 13.	0.7	21
136	An MCl inf4 p2? moiety (M = copper, zinc, cadmium and mercury) stabilized by bis(ethylenediamine)copper(II) cation. Transition Metal Chemistry, 1995, 20, 123.	0.7	5
137	N2S2 macrocyclic ligands. Synthesis and characterization of novel transition metal complexes of the type [LM(Si2Me6NH)2]2+ and [L?M(Si2Me6NH)2]2+. Transition Metal Chemistry, 1994, 19, 399.	0.7	O
138	Synthesis, structural insights, biological screening of DNA targeted Ru(âi)(Æž6-p-cymene) complexes containing bioactive amino-benzothiazole ligand scaffolds. New Journal of Chemistry, 0, , .	1.4	4